This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
3 Sector ETFs Gaining Momentum in May
by Sanghamitra Saha
After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.
Remdesivir Gets Emergency Approval: What's In Store for Gilead?
by Zacks Equity Research
In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Think Suppression, Not Recession: Global Week Ahead
by John Blank
Friday's U.S. nonfarm jobs report will be one for the record books. Before it arrives, Zacks Chief Strategist cautions: This is the mark of suppression, not recession. The choice of words does matter.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Moderna (MRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.